Rubenstein, James L <br/><br/>
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.  [electronic resource] 

 -  Blood advances  07 2018 
 - 1595-1607 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2473-9537 
<br/><br/><label>Standard No.: </label>10.1182/bloodadvances.2017014845  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Central Nervous System Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Lenalidomide--administration & dosage<br/>Lymphoma--drug therapy<br/>Maintenance Chemotherapy<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Rituximab--administration & dosage<br/>Survival Rate